552 related articles for article (PubMed ID: 27449671)
1. Factors associated with 10 years of continuous viral load suppression on HAART.
Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
[TBL] [Abstract][Full Text] [Related]
2. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
[TBL] [Abstract][Full Text] [Related]
4. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
Marconi VC; Grandits G; Okulicz JF; Wortmann G; Ganesan A; Crum-Cianflone N; Polis M; Landrum M; Dolan MJ; Ahuja SK; Agan B; Kulkarni H;
PLoS One; 2011; 6(5):e17956. PubMed ID: 21625477
[TBL] [Abstract][Full Text] [Related]
5. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.
Taiwo BO; Li X; Palella F; Jacobson LP; Margolick JB; Detels R; Rinaldo CR; Phair JP
HIV Med; 2009 Nov; 10(10):657-60. PubMed ID: 19601997
[TBL] [Abstract][Full Text] [Related]
6. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
Minidis NM; Mesner O; Agan BK; Okulicz JF
J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
[TBL] [Abstract][Full Text] [Related]
7. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
[TBL] [Abstract][Full Text] [Related]
8. Sustained HIV viral suppression following treatment interruption: an observational study.
Bedimo R; Chen RY; Westfall AO; Raper JL; Allison JJ; Saag MS
AIDS Res Hum Retroviruses; 2006 Jan; 22(1):40-4. PubMed ID: 16438644
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil.
Joao EC; Gouvêa MI; Menezes JA; Sidi LC; Cruz ML; Berardo PT; Ceci L; Cardoso CA; Teixeira Mde L; Calvet GA; Matos HJ
Int J STD AIDS; 2012 Jan; 23(1):44-7. PubMed ID: 22362687
[TBL] [Abstract][Full Text] [Related]
10. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.
Neilan AM; Karalius B; Patel K; Van Dyke RB; Abzug MJ; Agwu AL; Williams PL; Purswani M; Kacanek D; Oleske JM; Burchett SK; Wiznia A; Chernoff M; Seage GR; Ciaranello AL;
JAMA Pediatr; 2017 May; 171(5):450-460. PubMed ID: 28346597
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic outcomes of HAART-treated HIV-infected women in resource constrain settings: the Belgrade Study.
Dragović G; Salemović D; Ranin J; Nikolić J; Kušić J; Jevtović D
Women Health; 2014; 54(1):35-47. PubMed ID: 24555810
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713
[TBL] [Abstract][Full Text] [Related]
13. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
14. Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy.
Melku M; Abebe G; Teketel A; Asrie F; Yalew A; Biadgo B; Kassa E; Damtie D; Anlay DZ
Environ Health Prev Med; 2020 Aug; 25(1):43. PubMed ID: 32838734
[TBL] [Abstract][Full Text] [Related]
15. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
17. Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life.
Gill CJ; Griffith JL; Jacobson D; Skinner S; Gorbach SL; Wilson IB
J Acquir Immune Defic Syndr; 2002 Aug; 30(5):485-92. PubMed ID: 12154339
[TBL] [Abstract][Full Text] [Related]
18. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States.
Dale S; Cohen M; Weber K; Cruise R; Kelso G; Brody L
AIDS Patient Care STDS; 2014 Mar; 28(3):136-43. PubMed ID: 24568654
[TBL] [Abstract][Full Text] [Related]
19. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment.
Ironson G; O'Cleirigh C; Fletcher MA; Laurenceau JP; Balbin E; Klimas N; Schneiderman N; Solomon G
Psychosom Med; 2005; 67(6):1013-21. PubMed ID: 16314608
[TBL] [Abstract][Full Text] [Related]
20. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
